Deciphex Raises $11.5M in Series B Funding

Donal O’Shea, Chief Executive Officer, Decipher

Deciphex, Dublin, IrelandA $11.5 million deal was closed by a US-based provider of pathology software, and services. Series BRound of funding

Theround was led ACT Venture CapitalParticipation from Charles River Laboratories, NovartisIRRUS Investments, Nextsteps CapitalHBAN Medtech Syndicateas well as other investors. 

LedBy Donal O’Shea, Chief Executive Officer, Prof. Runjan Chetty, Chief Medical Officer, DecipherThe company is a software development company that focuses on digital pathology-based software for clinical and research pathology. InQ4 2021: The company launched its new clinical diagnostics service. Diagnexia. DiagnexiaOnline clinical pathology department. It provides remote access to subspecialty clinicians for primary diagnostics and secondary consultation services. This allows for faster case turnaround times and the delivery of the best patient care. 

TheThe company plans to use the funds to drive global growth and consolidate its position in the market. inClinical and non-clinical pathology are now possible through the use digital pathology and artificial Intelligence (AI), with a particular focus on improving its quality. PatholytixResearch pathology platform and launch of its DiagnexiaClinical service inThe United StatesAlong with ongoing expansion inThe UK Canada, Middle East.

In March2020 was the year that the company entered into a key strategic partnership agreement with a global preclinical CRO. Charles River Laboratories, International Inc. Pertainingto the codevelopment of AI tools for drug safety assessment.  Deciphex  is also a key member of BigPicture, a major EU funded initiative to build the world’s biggest central repository of digital pathology slides to boost the development of AI. 



Leave a Comment